01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
06:27 , Feb 27, 2019 |  BioCentury  |  Finance

Calypso finds its rhythm

Strong preclinical data and rising interest in IL-15 modulation enabled six-year-old Calypso Biotech B.V. to raise a €20 million ($22.6 million) series A round. The company hopes to start clinical trials next year of lead...
20:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

Vectura discontinues asthma therapy after Phase III miss

Vectura Group plc (LSE:VEC) said it will discontinue development of VR475 after both doses of the compound missed the primary endpoint in a Phase III trial to treat severe uncontrolled asthma. Both twice-daily 0.5 and...
18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Calliditas raises over $70M in Swedish IPO

Renal disease company Calliditas Therapeutics AB (SSE:CALTX) raised SEK650 million ($73.4 million) on June 15 through the sale of 14 million shares at SEK45 in an IPO on NASDAQ Stockholm. The company expects to begin...
16:33 , Apr 20, 2018 |  BC Week In Review  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...
23:02 , Apr 17, 2018 |  BC Extra  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...